Njuguna Henry, Gong Jian, Hutchinson Katie, Ndiaye Mamadou, Sabel Jennifer, Wasserman Cathy
Epidemic Intelligence Service, Division of Scientific Education and Professional Development, Centers for Disease Control and Prevention, United States.
Washington State Department of Health, United States.
Addict Behav Rep. 2021 May 28;14:100353. doi: 10.1016/j.abrep.2021.100353. eCollection 2021 Dec.
In the United States, overdose deaths resulting from methamphetamine and other amphetamine-type stimulants (METH/AMPH) have been increasing. We describe rates and characterize patients hospitalized after a METH/AMPH-involved overdose in Washington State, to guide prevention and control measures.
We conducted a trend analysis of hospitalized Washington State residents aged ≥15 years who received a METH/AMPH-involved overdose diagnosis in Washington's civilian hospitals and reported in the Comprehensive Hospital Abstract Reporting System.
We used Joinpoint regression analysis to study trends in rates of hospitalized patients who received a METH/AMPH-involved overdose diagnosis during 2010-2017. We used 2016-2017 data to describe characteristics of patients with nonfatal and fatal outcomes and used chi-square test (for categorical variables) and Wilcoxon rank-sum test (for continuous variables) to compare characteristics of patients by outcome.
During 2010-2017, 3587 patients were hospitalized and received a METH/AMPH-involved overdose diagnosis. The age-adjusted rate for METH/AMPH-involved overdose hospitalization increased from 6.3/100,000 persons in 2010 to 8.5/100,000 persons in 2017. Patients aged ≥55 years had the greatest increase in rate of overdose hospitalizations. Among these patients, 86% also had a substance use disorder diagnosis involving substances other than METH/AMPH, and 35% experienced a polysubstance overdose.
We observed increasing rates of METH/AMPH-involved overdose hospitalizations in Washington State, particularly among persons aged ≥55 years. Approximately a third of patients also experienced a polysubstance overdose, which can be considered when designing interventions to address increasing rates of overdose hospitalizations in Washington State.
在美国,甲基苯丙胺及其他苯丙胺类兴奋剂(METH/AMPH)导致的过量用药死亡人数一直在增加。我们描述了华盛顿州因涉及METH/AMPH的过量用药而住院的患者比例,并对这些患者进行特征分析,以指导预防和控制措施。
设计、地点、参与者:我们对华盛顿州年龄≥15岁、在该州民用医院接受涉及METH/AMPH过量用药诊断并在综合医院摘要报告系统中报告的住院居民进行了趋势分析。
我们使用Joinpoint回归分析研究2010 - 2017年期间接受涉及METH/AMPH过量用药诊断的住院患者比例的趋势。我们使用2016 - 2017年的数据描述非致命和致命结局患者的特征,并使用卡方检验(用于分类变量)和Wilcoxon秩和检验(用于连续变量)按结局比较患者特征。
在2010 - 2017年期间,3587名患者住院并接受了涉及METH/AMPH的过量用药诊断。涉及METH/AMPH的过量用药住院的年龄调整率从2010年的6.3/10万人增加到2017年的8.5/10万人。年龄≥55岁的患者过量用药住院率增长最大。在这些患者中,86%还被诊断患有除METH/AMPH之外的物质使用障碍,35%经历了多药滥用过量。
我们观察到华盛顿州涉及METH/AMPH的过量用药住院率在上升,特别是在年龄≥55岁的人群中。约三分之一的患者还经历了多药滥用过量,在设计干预措施以应对华盛顿州不断上升的过量用药住院率时可考虑这一点。